These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9615861)

  • 1. Discovery of podophyllotoxins.
    Imbert TF
    Biochimie; 1998 Mar; 80(3):207-22. PubMed ID: 9615861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007.
    Xu H; Lv M; Tian X
    Curr Med Chem; 2009; 16(3):327-49. PubMed ID: 19149581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: an update (2008-2010).
    Lv M; Xu H
    Mini Rev Med Chem; 2011 Sep; 11(10):901-9. PubMed ID: 21781026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture.
    Stähelin HF; von Wartburg A
    Cancer Res; 1991 Jan; 51(1):5-15. PubMed ID: 1988106
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytotoxic cyclolignans related to podophyllotoxin.
    Gordaliza M; Miguel del Corral JM; Angeles Castro M; García-García PA; San Feliciano A
    Farmaco; 2001 Apr; 56(4):297-304. PubMed ID: 11421258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor properties of podophyllotoxin and related compounds.
    Gordaliza M; Castro MA; del Corral JM; Feliciano AS
    Curr Pharm Des; 2000 Dec; 6(18):1811-39. PubMed ID: 11102564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16).
    Long BH
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):3-19. PubMed ID: 1329225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments towards podophyllotoxin congeners as potential apoptosis inducers.
    Kamal A; Hussaini SM; Malik MS
    Anticancer Agents Med Chem; 2015; 15(5):565-74. PubMed ID: 25469512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity.
    Yusenko M; Jakobs A; Klempnauer KH
    Sci Rep; 2018 Sep; 8(1):13159. PubMed ID: 30177851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives.
    Gordaliza M; García PA; del Corral JM; Castro MA; Gómez-Zurita MA
    Toxicon; 2004 Sep; 44(4):441-59. PubMed ID: 15302526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
    Hartmann JT; Lipp HP
    Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor agents. 100. Inhibition of human DNA topoisomerase II by cytotoxic ether and ester derivatives of podophyllotoxin and alpha-peltatin.
    Thurston LS; Imakura Y; Haruna M; Li DH; Liu ZC; Liu SY; Cheng YC; Lee KH
    J Med Chem; 1989 Mar; 32(3):604-8. PubMed ID: 2537424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide: four decades of development of a topoisomerase II inhibitor.
    Hande KR
    Eur J Cancer; 1998 Sep; 34(10):1514-21. PubMed ID: 9893622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic and application perspectives of azapodophyllotoxins: alternative scaffolds of podophyllotoxin.
    Kumar A; Kumar V; Alegria AE; Malhotra SV
    Curr Med Chem; 2011; 18(25):3853-70. PubMed ID: 21824101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From podophyllotoxin glucoside to etoposide.
    Stähelin H; von Wartburg A
    Prog Drug Res; 1989; 33():169-266. PubMed ID: 2687938
    [No Abstract]   [Full Text] [Related]  

  • 16. Podophyllotoxin: History, Recent Advances and Future Prospects.
    Shah Z; Gohar UF; Jamshed I; Mushtaq A; Mukhtar H; Zia-Ui-Haq M; Toma SI; Manea R; Moga M; Popovici B
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current development of podophyllotoxins.
    Canetta R; Hilgard P; Florentine S; Bedogni P; Lenaz L
    Cancer Chemother Pharmacol; 1982; 7(2-3):93-8. PubMed ID: 7044596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podophyllotoxins: current status and recent developments.
    Damayanthi Y; Lown JW
    Curr Med Chem; 1998 Jun; 5(3):205-52. PubMed ID: 9562603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
    Pettit GR; Searcy JD; Tan R; Cragg GM; Melody N; Knight JC; Chapuis JC
    J Nat Prod; 2016 Mar; 79(3):507-18. PubMed ID: 26938998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26.
    Minocha A; Long BH
    Biochem Biophys Res Commun; 1984 Jul; 122(1):165-70. PubMed ID: 6331440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.